This trial is no longer recruiting

Recruitment for this study has ended, so applications are closed. You can still read the trial details, or browse similar trials that are currently recruiting.

Not recruiting
Phase 2

PF-07976016

Sponsor:

Pfizer

Code:

NCT06717425

Conditions

Obesity

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

PF-07976016

Placebo

Study Details

Brief summary:

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07976016) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-07976016) to those of participants who take placebo (a lookalike substance that contains no active study medicine). The aim is to measure the body's response to the study medicine, including any changes in participants' body weight and how well they tolerate the study medicine.

Conditions

Obesity

Study ID

NCT06717425

Start date

Dec 9, 2024

Status verified date

Dec, 2024

Completion date

Jan 17, 2026

Anticipated

Primary completion date

Dec 13, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Key Inclusion Criteria:

  • Male or non-pregnant, non-breastfeeding female, 18 to 74 years of age at Visit 1
  • Body Mass Index ≥30.0 kg/m2 at Visit 1, with stable body weight, defined as <5 kg change in the 12 weeks before Visit 1
  • Eligible and willing to receive required background medicine
  • Willing and able to comply with all study procedures

Key Exclusion Criteria:

  • Any medical or psychiatric condition or laboratory abnormality, or recent serious illness or hospitalization, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study including diagnosis of type 2 diabetes mellitus, type 1 or secondary forms of diabetes.
  • Use of any prohibited prior or concomitant medication(s)
  • Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests at Visit 1.

Study Design

Enrollment

252 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: PF-07976016 Dose 1

experimental: PF-07976016 Dose 2

experimental: PF-07976016 Dose 3

placebo comparator: Placebo

Interventions

PF-07976016

Taken once daily

Placebo

Taken once daily

Primary outcome measure

  • Percent change from baseline in body weight [ Time Frame: Baseline to Week 16 ]

Central Contacts and Locations

Central contacts

Pfizer CT.gov Call Center

1-800-718-1021ClinicalTrials.gov_Inquiries@pfizer.com

Locations

Rophe Adult and Pediatric Medicine/SKYCRNG

Recruiting

Union City, Georgia, United States, 30291

L-MARC Research Center

Recruiting

Louisville, Kentucky, United States, 40213

More Information

Sponsor

Pfizer

Last update posted

Dec 24, 2024

Last verified

Dec, 2024

Keywords

  • Obesity

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-23. This information was provided to ClinicalTrials.gov by Pfizer on 2024-12-24. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.